AU2013318283A1 - Dihydropyrrolidino-pyrimidines as kinase inhibitors - Google Patents

Dihydropyrrolidino-pyrimidines as kinase inhibitors Download PDF

Info

Publication number
AU2013318283A1
AU2013318283A1 AU2013318283A AU2013318283A AU2013318283A1 AU 2013318283 A1 AU2013318283 A1 AU 2013318283A1 AU 2013318283 A AU2013318283 A AU 2013318283A AU 2013318283 A AU2013318283 A AU 2013318283A AU 2013318283 A1 AU2013318283 A1 AU 2013318283A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
optionally substituted
amino
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013318283A
Other languages
English (en)
Inventor
Michael Patrick Dillon
Mika Lindvall
Daniel Poon
Savithri Ramurthy
Vivek RAUNIYAR
Cynthia Shafer
Sharadha Subramanian
Huw Tanner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013318283A1 publication Critical patent/AU2013318283A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2013318283A 2012-09-19 2013-09-17 Dihydropyrrolidino-pyrimidines as kinase inhibitors Abandoned AU2013318283A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702981P 2012-09-19 2012-09-19
US61/702,981 2012-09-19
PCT/US2013/060032 WO2014047020A1 (en) 2012-09-19 2013-09-17 Dihydropyrrolidino-pyrimidines as kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2013318283A1 true AU2013318283A1 (en) 2015-03-05

Family

ID=49274870

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013318283A Abandoned AU2013318283A1 (en) 2012-09-19 2013-09-17 Dihydropyrrolidino-pyrimidines as kinase inhibitors

Country Status (13)

Country Link
US (1) US9546173B2 (enExample)
EP (1) EP2897961B1 (enExample)
JP (1) JP6186440B2 (enExample)
KR (1) KR20150056550A (enExample)
CN (1) CN104640865B (enExample)
AU (1) AU2013318283A1 (enExample)
BR (1) BR112015005982A2 (enExample)
CA (1) CA2882410A1 (enExample)
EA (1) EA201590600A1 (enExample)
ES (1) ES2612885T3 (enExample)
IN (1) IN2015DN01328A (enExample)
MX (1) MX2015003535A (enExample)
WO (1) WO2014047020A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882410A1 (en) * 2012-09-19 2014-03-27 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
JP7349491B2 (ja) 2018-07-12 2023-09-22 ユーシービー バイオファルマ エスアールエル Ｉｌ－１７モジュレーターとしてのスピロ環状インダン類似体
WO2020243457A1 (en) * 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
AU2020319888A1 (en) * 2019-08-01 2022-02-24 Praetego, Inc. Inhibitors of advanced glycation end products
PL4073044T3 (pl) * 2019-12-10 2025-05-19 F. Hoffmann-La Roche Ag Nowe inhibitory BRAF jako związki przełamujące paradoks
PL4073065T3 (pl) 2019-12-10 2025-05-19 F. Hoffmann-La Roche Ag Nowe pochodne metylochinazolinonu
CN115443274B (zh) * 2020-04-30 2025-04-25 勤浩医药（苏州）有限公司 含苯基并内磺酰胺的化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4530852B2 (ja) * 2002-07-15 2010-08-25 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP2007513172A (ja) * 2003-12-02 2007-05-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド 複素環式プロテインキナーゼインヒビターおよびその使用
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
BRPI0518509A2 (pt) 2005-01-10 2008-11-25 Pfizer pirrolopirazàis, inibidores de cinase potentes
HRP20110892T1 (hr) 2005-12-13 2011-12-31 Schering Corporation Policiklični derivati indazola koji su inhibitori erk
BRPI0812450A2 (pt) 2007-06-05 2019-09-24 Schering Corp derivados de indazol policíclicos e seu uso como inibidores de erk para o tratamento de câncer
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) * 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
JP2013542965A (ja) 2010-11-17 2013-11-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍の治療方法
BR112013021896A2 (pt) * 2011-02-28 2016-11-08 Array Biopharma Inc inibidores de serina/treonina cinase
JP2015508785A (ja) 2012-03-02 2015-03-23 ジェネンテック， インコーポレイテッド ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体
CA2882410A1 (en) * 2012-09-19 2014-03-27 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors

Also Published As

Publication number Publication date
EP2897961A1 (en) 2015-07-29
US9546173B2 (en) 2017-01-17
IN2015DN01328A (enExample) 2015-07-03
CA2882410A1 (en) 2014-03-27
WO2014047020A1 (en) 2014-03-27
EA201590600A1 (ru) 2015-07-30
MX2015003535A (es) 2015-07-14
CN104640865B (zh) 2018-05-11
CN104640865A (zh) 2015-05-20
JP6186440B2 (ja) 2017-08-23
EP2897961B1 (en) 2016-10-26
ES2612885T3 (es) 2017-05-19
BR112015005982A2 (pt) 2017-07-04
KR20150056550A (ko) 2015-05-26
US20150274733A1 (en) 2015-10-01
JP2015529248A (ja) 2015-10-05

Similar Documents

Publication Publication Date Title
EP3968999B1 (en) Fgfr inhibitors and methods of use thereof
KR102849047B1 (ko) 피롤로피리미딘 itk 억제제
JP2023071767A (ja) Ｂｒｍ標的化化合物および関連使用方法
TW202246255A (zh) Ｃｄｋ抑制劑及其使用方法
JP2024532734A (ja) 複素環式化合物及び使用方法
AU2016287335B2 (en) TBK/IKKepsilon inhibitor compounds and uses thereof
JP2021519337A (ja) Ｉｋａｒｏｓの分解のためのセレブロン結合剤
EP3455219A1 (en) Amine-linked c3-glutarimide degronimers for target protein degradation
EP2897961B1 (en) Dihydropyrrolidino-pyrimidines as kinase inhibitors
JP2016504990A (ja) Ｂｅｔタンパク質抑制性ジヒドロピリドピラジノン
JP2018520992A (ja) アミドで置換されているシクロヘキサン誘導体
HK1212972A1 (zh) 作爲bet-蛋白抑制剂用於治疗过度增殖性疾病的吡咯并-和吡唑并-三唑并二氮杂卓
CA3199082A1 (en) Heterocyclic spiro compounds and methods of use
US20230399327A1 (en) High activity hpk1 kinase inhibitor
KR20150090044A (ko) 아자퀴나졸린 카복사미드 유도체
AU2016349148C1 (en) 1,4-dicarbonyl-piperidyl derivatives
WO2024044570A1 (en) Compounds and methods for modulating her2
CA3154136C (en) MLL-1 INHIBITORS AND ANTICANCER AGENTS
CN116249696B (zh) 嘧啶酮类化合物及其用途
CA2989684C (en) Hpk1 inhibitors and methods of using same
NZ624021B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted